Paracetamol IV Market Growth, Trends, Size, Analysis, CAGR Status, Demand and Future Outlook
Paracetamol IV Market Growth, Size, Trends Analysis - By Indication, By Application, By End Use - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Feb-2025 | Report ID: HLCA2539 | Pages: 1 - 233 | Formats*: |
| Category : Healthcare | |||
Paracetamol IV Market Introduction and Overview
According to SPER Market Research, the Global Paracetamol IV Market is estimated to reach USD 1150.18 million by 2034 with a CAGR of 3.72%.
The report includes an in-depth analysis of the Global Paracetamol IV Market, including market size and trends, product mix, Applications, and supplier analysis. The primary factors driving this treatment's expansion are its application in post-operative pain management and fever reduction. An efficient treatment option that significantly reduces pain is intravenous paracetamol. The market has also grown as a result of the increasing acceptance of mixing intravenous paracetamol with NSAIDs and opioids. The growing need for all-encompassing pain management choices in clinical settings is satisfied by this combination approach, which provides a whole post-operative pain management solution. Risks such as hepatotoxicity and anaphylaxis provide difficulties for the worldwide paracetamol IV market, necessitating careful administration and continued study.
By Indication: The pain management segment dominates the market, driven by the need for effective postoperative pain relief and a growing shift away from opioids. This shift supports improved patient care and aligns with evolving clinical practices. The pyrexia (fever) segment is poised for significant growth due to the increasing prevalence of fever-related conditions, with healthcare providers focusing on intravenous formulations for fast symptom relief. As awareness of fever management rises, this segment will be crucial for future market development, highlighting the strategic role of paracetamol IV in clinical settings.
By Application: The surgical application segment leads the market, driven by high demand for postoperative care and paracetamol IV’s effectiveness in pain management and reducing opioid use. Its ability to provide quick pain relief supports faster recovery, driving adoption in healthcare settings. The growing number of surgeries globally strengthens this segment’s dominance. Meanwhile, the non-surgical application segment is expected to grow significantly, fueled by the increasing need for pain and fever management outside of surgeries. Paracetamol IV's effectiveness in emergency and outpatient care will further support this expansion.
By End Use: The hospital segment leads the market, driven by the growing number of surgeries and hospital admissions requiring effective pain management. Hospitals are key settings for administering intravenous paracetamol, especially for postoperative patients needing rapid pain and fever relief. The rising preference for non-opioid analgesics and established treatment protocols further boost paracetamol IV adoption, reinforcing the segment's market dominance.
By Regional Insights: North America leads the global paracetamol IV market, driven by high demand for pain management in hospitals and surgical settings. Advanced healthcare infrastructure, regulatory support, and rising surgical procedures contribute to market growth. Strategic partnerships and innovations in formulations reinforce its position, with a growing focus on non-opioid alternatives.
Market Competitive Landscape:
Abbott, Aurobindo Pharma, Bristol-Myers Squibb Company, Cipla Inc., Dr Reddy's Laboratories Ltd., Lupin, Mallinckrodt (Mallinckrodt Pharmaceuticals), Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Limited, and others.
Recent Developments:
- Hyloris Pharmaceuticals and Halex Istar signed a licensing and distribution deal for Maxigesic IV in Brazil in July 2024, expanding the availability of this non-opioid pain reliever in one of the biggest markets in South America. Maxigesic IV, which aims to assist combat the rising opioid use in Brazil, mixes ibuprofen and paracetamol for better post-operative pain treatment.
- Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) and Salus Pharmaceuticals announced in January 2023 that they will work together to exclusively license and distribute Maxigesic IV throughout nine European nations. Launches are anticipated later in 2023 for this dual-action, non-opioid intravenous pain reliever, which combines ibuprofen and paracetamol. It is now registered in five of these markets. This partnership is in line with Hyloris's plan to repurpose current drugs and increase access to cutting-edge, non-opioid pain relief alternatives.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Indication, By Application, By End Use. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | Abbott, Aurobindo Pharma, Bristol-Myers Squibb Company, Cipla Inc., Dr Reddy's Laboratories Ltd., Lupin, Mallinckrodt (Mallinckrodt Pharmaceuticals), Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Limited, and others. |
Key Topics Covered in the Report:
- Global Paracetamol IV Market Size (FY’2021-FY’2034)
- Overview of Global Paracetamol IV Market
- Segmentation of Global Paracetamol IV Market By Indication {(Pain, Pyrexia (Fever)}
- Segmentation of Global Paracetamol IV Market By Application (Surgical, Non-surgical)
- Segmentation of Global Paracetamol IV Market By End Use (Hospitals, Clinics, Others)
- Statistical Snap of Global Paracetamol IV Market
- Expansion Analysis of Global Paracetamol IV Market
- Problems and Obstacles in Global Paracetamol IV Market
- Competitive Landscape in the Global Paracetamol IV Market
- Details on Current Investment in Global Paracetamol IV Market
- Competitive Analysis of Global Paracetamol IV Market
- Prominent Players in the Global Paracetamol IV Market
- SWOT Analysis of Global Paracetamol IV Market
- Global Paracetamol IV Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Paracetamol IV Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Paracetamol IV Market
7. Global Paracetamol IV Market, By Indication, (USD Million) 2021-2034
7.1. Pain7.2. Pyrexia (Fever)
8. Global Paracetamol IV Market, By Application, (USD Million) 2021-2034
8.1. Surgical8.2. Non-surgical
9. Global Paracetamol IV Market, By End Use (USD Million) 2021-2034
9.1. Hospitals9.2. Clinics9.3. Others
10. Global Paracetamol IV Market, (USD Million) 2021-2034
10.1. Global Paracetamol IV Market Size and Market Share
11. Global Paracetamol IV Market, By Region, (USD Million) 2021-2034
11.1. Asia-Pacific
11.1.1. Australia11.1.2. China11.1.3. India11.1.4. Japan11.1.5. South Korea
11.1.6. Rest of Asia-Pacific
11.2. Europe
11.2.1. France11.2.2. Germany11.2.3. Italy11.2.4. Spain11.2.5. United Kingdom11.2.6. Rest of Europe
11.3. Middle East and Africa
11.3.1. Kingdom of Saudi Arabia11.3.2. United Arab Emirates11.3.3. Qatar11.3.4. South Africa11.3.5. Egypt11.3.6. Morocco11.3.7. Nigeria
11.3.8. Rest of Middle-East and Africa
11.4. North America
11.4.1. Canada11.4.2. Mexico11.4.3. United States
11.5. Latin America
11.5.1. Argentina11.5.2. Brazil11.5.3. Rest of Latin America
12. Company Profile
12.1. Abbott
12.1.1. Company details12.1.2. Financial outlook12.1.3. Product summary12.1.4. Recent developments
12.2. Aurobindo Pharma
12.2.1. Company details12.2.2. Financial outlook12.2.3. Product summary12.2.4. Recent developments
12.3. Bristol-Myers Squibb Company
12.3.1. Company details12.3.2. Financial outlook12.3.3. Product summary12.3.4. Recent developments
12.4. Cipla Inc.
12.4.1. Company details12.4.2. Financial outlook12.4.3. Product summary12.4.4. Recent developments
12.5. Dr Reddy's Laboratories Ltd.
12.5.1. Company details12.5.2. Financial outlook12.5.3. Product summary12.5.4. Recent developments
12.6. Lupin
12.6.1. Company details12.6.2. Financial outlook12.6.3. Product summary12.6.4. Recent developments
12.7. Mallinckrodt (Mallinckrodt Pharmaceuticals)
12.7.1. Company details12.7.2. Financial outlook12.7.3. Product summary12.7.4. Recent developments
12.8. Novartis AG
12.8.1. Company details12.8.2. Financial outlook12.8.3. Product summary12.8.4. Recent developments
12.9. Pfizer Inc.
12.9.1. Company details12.9.2. Financial outlook12.9.3. Product summary12.9.4. Recent developments
12.10. Sanofi
12.10.1. Company details12.10.2. Financial outlook12.10.3. Product summary12.10.4. Recent developments
12.11. Sun Pharmaceutical Industries Limited
12.11.1. Company details12.11.2. Financial outlook12.11.3. Product summary12.11.4. Recent developments
12.12. Others
13. Conclusion
14. List of Abbreviations
15. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Paracetamol IV Market is projected to reach USD 1150.18 million by 2034, growing at a CAGR of 3.72% during the forecast period.
Paracetamol IV Market grew in Market size from 2025. The Market is expected to reach USD 1150.18 million by 2034, at a CAGR of 3.72% during the forecast period.
Paracetamol IV Market CAGR of 3.72% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Paracetamol IV Market size is USD 1150.18 million from 2025 to 2034.
Paracetamol IV Market is covered By Indication, By Application, By End Use.
The North America is anticipated to have the highest Market share in the Paracetamol IV Market.
The key players in the Market include Companies Abbott, Aurobindo Pharma, Bristol-Myers Squibb Company, Cipla Inc., Dr Reddy's Laboratories Ltd., Lupin, Mallinckrodt (Mallinckrodt Pharmaceuticals), Novartis AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Limited, and others.
An efficient treatment option that significantly reduces pain is intravenous paracetamol. The market has also grown as a result of the increasing acceptance of mixing intravenous paracetamol with NSAIDs and opioids.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
